- Home
- FT vs CHRS Comparison
FT vs CHRS Comparison
Compare FT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- CHRS
- Stock Information
- Founded
- FT 1988
- CHRS 2010
- Country
- FT United States
- CHRS United States
- Employees
- FT N/A
- CHRS N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FT Finance
- CHRS Health Care
- Exchange
- FT Nasdaq
- CHRS Nasdaq
- Market Cap
- FT 187.3M
- CHRS 84.2M
- IPO Year
- FT N/A
- CHRS 2014
- Fundamental
- Price
- FT $7.69
- CHRS $0.80
- Analyst Decision
- FT
- CHRS Buy
- Analyst Count
- FT 0
- CHRS 3
- Target Price
- FT N/A
- CHRS $4.68
- AVG Volume (30 Days)
- FT 63.0K
- CHRS 1.3M
- Earning Date
- FT 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- FT 7.85%
- CHRS N/A
- EPS Growth
- FT N/A
- CHRS N/A
- EPS
- FT N/A
- CHRS N/A
- Revenue
- FT N/A
- CHRS $272,251,000.00
- Revenue This Year
- FT N/A
- CHRS N/A
- Revenue Next Year
- FT N/A
- CHRS $106.56
- P/E Ratio
- FT N/A
- CHRS N/A
- Revenue Growth
- FT N/A
- CHRS 19.87
- 52 Week Low
- FT $5.97
- CHRS $0.66
- 52 Week High
- FT $7.23
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FT 68.81
- CHRS 51.58
- Support Level
- FT $7.43
- CHRS $0.72
- Resistance Level
- FT $7.53
- CHRS $0.77
- Average True Range (ATR)
- FT 0.07
- CHRS 0.04
- MACD
- FT 0.02
- CHRS 0.01
- Stochastic Oscillator
- FT 99.49
- CHRS 85.96
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.